Warmbrunn Jakob, Straube Christoph, Haase Hans-Ulrich, Sinnecker Daniel, Laugwitz Karl-Ludwig, Combs Stephanie E, Schneider Simon, Habermehl Daniel
TUM School of Medicine and Health, Department of Radiation Oncology, Technische Universität München (TUM), Klinikum rechts der Isar, Munich, Germany.
TUM School of Medicine and Health, Department of Internal Medicine I, Technische Universität München (TUM), Klinikum rechts der Isar, Munich, Germany.
Strahlenther Onkol. 2025 Apr;201(4):463-471. doi: 10.1007/s00066-024-02345-0. Epub 2025 Jan 10.
Increasing life expectancy and advances in cancer treatment will lead to more patients needing both radiation therapy (RT) and cardiac implantable electronic devices (CIEDs). CIEDs, including pacemakers and defibrillators, are essential for managing cardiac arrhythmias and heart failure. Telemetric monitoring of CIEDs checks battery status, lead function, settings, and diagnostic data, thereby identifying software deviations or damage. This study evaluates the German Society for Radiation Oncology (DEGRO)/German Society for Cardiology (DGK) guideline, assessing real-world complications and risk factors and analyzing pacemaker and implantable cardioverter-defibrillator (ICD) lead function for their predictive value concerning device malfunction.
A total of 54 patients with pacemakers or ICDs who underwent radiation therapy were identified. Demographics, treatment courses, and device information from physical and digital records were extracted. DEGRO/DGK risk groups and pacemaker dependency at the start of RT were assessed. Delineation of the devices and lead insertion sites was performed in the treatment planning system. Dosimetric information from the treatment plans was then correlated with reports of standardized device checks.
Over 80% of patients were treated with dual-chamber pacemakers or cardiac resynchronization therapy (CRT), and 16.7% had ICDs. One third of patients were pacemaker dependent. 59.3% of patients were in the low-risk category, 29.3% in the medium-risk, and 11.1% in the high-risk category. Thoracic irradiation resulted in the highest median dose to devices. Lead parameter deviations exceeding thresholds were found in 14.8% for the stimulation threshold and 13.5% for sensing. Device malfunctions occurred in 3.7% of cases, both involving electrical resets and neutron-producing radiation (beam energy 10 megaelectron volt (MV) or higher).
Collecting lead parameters in addition to secure malfunctions like electrical restarts and memory erasure revealed a significant proportion of treatment courses with temporary changes, though no correlation with individual treatment plans or adverse events was found. The focus on reducing neutron-producing radiation could be further supported.
预期寿命的延长和癌症治疗的进展将导致更多患者既需要放射治疗(RT)又需要心脏植入式电子设备(CIED)。CIED包括起搏器和除颤器,对于管理心律失常和心力衰竭至关重要。CIED的遥测监测可检查电池状态、导线功能、设置和诊断数据,从而识别软件偏差或损坏。本研究评估了德国放射肿瘤学会(DEGRO)/德国心脏病学会(DGK)指南,评估实际并发症和风险因素,并分析起搏器和植入式心律转复除颤器(ICD)导线功能对设备故障的预测价值。
共确定了54例接受放射治疗的起搏器或ICD患者。从物理和数字记录中提取人口统计学、治疗过程和设备信息。评估RT开始时的DEGRO/DGK风险组和起搏器依赖性。在治疗计划系统中对设备和导线插入部位进行勾画。然后将治疗计划中的剂量学信息与标准化设备检查报告相关联。
超过80%的患者接受了双腔起搏器或心脏再同步治疗(CRT),16.7%的患者有ICD。三分之一的患者依赖起搏器。59.3%的患者属于低风险类别,29.3%属于中等风险,11.1%属于高风险类别。胸部照射导致设备的中位剂量最高。刺激阈值超过阈值的导线参数偏差为14.8%,感知偏差为13.5%。3.7%的病例发生设备故障,均涉及电重置和产生中子的辐射(束能量10兆电子伏特(MV)或更高)。
除了像电重启和内存擦除这样的安全故障外,收集导线参数显示出相当比例的治疗过程有临时变化,尽管未发现与个体治疗计划或不良事件有相关性。对减少产生中子的辐射的关注可得到进一步支持。